A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Recruiting

Phase 3

NerandomilastA Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Sponsor:

Boehringer Ingelheim

Code:

NCT07201922

Conditions

Familial Pulmonary Fibrosis

Interstitial Lung Abnormalities

Interstitial Lung Diseases

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

Nerandomilast

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-20. This information was provided to ClinicalTrials.gov by Boehringer Ingelheim on 2026-05-14.